Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Hosting Analyst R&D Day Today
SAN DIEGO , May 24, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will host a live webcast of its Analyst R&D Day today beginning at 11:00 a.m.
View HTML
Toggle Summary Vital Therapies to Host Analyst R&D Day on May 24, 2018
SAN DIEGO , May 11, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will host a live webcast of its Analyst R&D Day on Thursday, May 24, 2018 beginning at 11:00 a.m.
View HTML
Toggle Summary Vital Therapies Announces First Quarter 2018 Financial Results
- VTL-308 Enrollment Completed with 151 Subjects - On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms
View HTML
Toggle Summary Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call with Webcast
SAN DIEGO , April 26, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2018 financial results after the market closes on Tuesday, May
View HTML
Toggle Summary Vital Therapies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 25, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported grants under its Amended and Restated 2017 Inducement Equity Incentive Plan to
View HTML
Toggle Summary Vital Therapies Announces VTL-308 Reaches Enrollment Target of 150 Subjects
Topline Results for VTL-308 Expected in the Third Quarter of 2018 SAN DIEGO , March 22, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the
View HTML
Toggle Summary Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results
- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12 - On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO , March 13, 2018 (GLOBE NEWSWIRE) --   Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy
View HTML
Toggle Summary Vital Therapies Announces Upcoming Fourth Quarter and Full Year Financial Results Conference Call with Webcast and Participation in Upcoming Conference
SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2017 financial results after the market closes on
View HTML
Toggle Summary Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported a grant under its 2017 Inducement Equity Incentive Plan to Russell Cox , who
View HTML
Toggle Summary Vital Therapies Added to NASDAQ Biotechnology Index
SAN DIEGO , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, which
View HTML